康希诺：吸入用结核病加强疫苗印尼启动Ⅰ期临床试验并完成首例受试者入组

Group 1 - The core point of the article is that CanSino (688185) has announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, with the first subject enrolled in the trial [1] Group 2 - The vaccine is referred to as the "inhaled tuberculosis booster vaccine" and utilizes a type 5 adenoviral vector [1] - The announcement was made on November 13, indicating the company's progress in vaccine development [1]